Nigel Ten Fleming is a highly successful serial entrepreneur in the biotechnology and pharmaceuticals sectors with a passion for solving strategic challenges and finding efficient ways to monetize cutting-edge science for the betterment of healthcare. Among the highlights of his career was the founding of Athena Diagnostics, a physician-focused diagnostics company that sold for $740 million USD in 2011. With a Ph.D. in Clinical Biochemistry, he has also served on numerous boards and gained expertise in board strategies, strategic planning, fundraising, venture capital, licensing deals, collaborative research agreements, partnerships, company sales, and asset liquidation.

Fleming's extensive education includes a postdoc in Diabetes from Boston University, a Brief Executive Refresher in Agribusiness Executive Course from Harvard Business School, and a BA degree in Interdisciplinary Studies with Highest Honors from the University of North Carolina at Chapel Hill. He has also studied lecturing in Biochemistry at Harvard Medical School and catalan language classes through Palafrugell Language Classes.

Fleming's professional experience includes former roles as CEO and Co-Founder of Adventura Capital SL, Executive Director and board member of A-CUBE Inc, Founder and Chairman of Minerva Healthcare Inc, and Founder and CEO of Polyclonal Sera Labs. He has also served on the board of directors of various companies, including Impax Laboratories and Serenus Biotherapeutics.